Pfizer, Inc.: analysis of patenting 1998 – 2001

This article complements earlier reviews (1995 and 1998) of Pfizer’s patenting policies and examines how the acquisition of Warner-Lambert has affected the new Pfizer’s patent portfolio. It compares the patenting activity across each major therapeutic area with the company’s 2001 revenues. This highlights how the patenting activity suggests that Pfizer is starting to build a portfolio of potential anticancer products and is showing increased interest in the identification of novel anti-inflammatory agents. These findings are complemented by considerable efforts to support its existing large cardiovascular and CNS franchises.